Darius M. Moshfeghi, MD, FASRS
Professional Affiliations
Academic Appointments- Stanford University School of Medicine
Education and Training
- Retinal fellowship
- Cleveland Clinic, Cole Eye Institute, Cleveland, OH
- Additional fellowship
- Ocular Oncology & Orbital Disease, Memphis, TN
- Ophthalmology residency
- Tulane University, New Orleans, LA
- Internship
- Tulane University Medical School, New Orleans, LA
- Medical School
- Tulane University School of Medicine, New Orleans, LA
- College
- Tulane University, New Orleans, LA
Biography
Darius M. Moshfeghi, MD, is Professor and Chief of Retina at the Byers Eye Institute at the Stanford University School of Medicine where he established the vitreoretinal fellowship program. He is internationally recognized for his pioneering work to promote telemedicine for the prevention of blindness in premature and term infants, establishing the Stanford University Network for the Diagnosis of Retinopathy of Prematurity (SUNDROP) network in 2005. Dr. Moshfeghi has led the Telemedicine for ROP screening program (TeleROP) collaboration between Stanford University and Pediatrix since 2017. SUNDROP and TeleROP provide ROP screening coverage for >2% of USA neonatal intensive care units.
He is a founding member of the Collaborative Community on Ophthalmic Imaging—ROP section which works with the FDA to develop guidelines for new technology and currently serves on the American Academy of Ophthalmology Telemedicine Working Group and previously was a member of the ROP Telemedicine Task Force Panel.
He led the steering committee for the Regeneron BUTTERFLEYE trial and the photographic imaging committee for Bayer FIREFLEYE trial of aflibercept for ROP. He leads the scientific advisory boards for Akebia, Feliqs, and Aspire Pharma for their prevention trials in ROP.
He is active in Data Monitoring Safety Boards working with Affamed, Alcon, Icon Clinical Research, Insite DME, Novartis, and Vanotech Chengdu.
His entrepreneurial work centers around telemedicine applications in eye health: he founded and was Chairman of Placid0 until its acquisition by Waldo, Inc., in November of 2021, served on the Board of directors of 1800 Contacts until its acquisition by KKR in November of 2020. Dr. Moshfeghi teamed with Dr. Jochen Kumm to form Pr3vent to implement universal newborn eye screening for retinal and ocular abnormalities in healthy newborn infants.
Dr. Moshfeghi was inducted into the 2021 class of the Retina Hall of Fame and is a member of the Club Jules Gonin, Retina Society, Macula Society, American Society of Retinal Specialists, and the Association of Pediatric Retinal Specialists.